Senstend
lidocaine / prilocaine
Table of contents
Overview
The marketing authorisation for Senstend has been withdrawn at the request of the marketing-authorisation holder.
-
List item
Senstend : EPAR - Medicine overview (PDF/670.21 KB)
First published: 29/11/2019
Last updated: 05/07/2022
EMA/519240/2019 -
-
List item
Senstend : EPAR - Risk-management-plan summary (PDF/1.21 MB)
First published: 29/11/2019
Last updated: 05/07/2022
Authorisation details
| Product details | |
|---|---|
| Name |
Senstend
|
| Agency product number |
EMEA/H/C/005298
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
|
| Therapeutic area (MeSH) |
Premature Ejaculation
|
| Anatomical therapeutic chemical (ATC) code |
N01BB20
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Plethora Pharma Solutions Limited
|
| Date of issue of marketing authorisation valid throughout the European Union |
14/11/2019
|
| Contact address |
32 Merrion Street |
Product information
14/11/2019 Senstend - EMEA/H/C/005298 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Anesthetics
Therapeutic indication
Senstend is indicated for the treatment of primary premature ejaculation in adult men.